Redeye is positive about Renaparin’s five-year follow-up data.
* NOI -2% y-o-y, 0.6% vs ABGSCe, -0.4% vs cons. * Value changes of -0.
After the recent announcements of a divestment and implementation of additional efficiency measures ...
* Signs of stabilisation but pricing remains pressured * We leave our estimates broadly unchanged * ...
We believe Q2 has had a better set-up compared to prior quarters as both BD and Wound Management rev...
We see Q2 revenue declining y/y, due to fewer starts and completions, but higher margins.
We expect Lassila & Tikanoja (L&T) to face pressure from a rise in diesel and gate prices in Q2.
Scandinavian ChemoTech has announced the early publication of an independent clinical abstract ahead...
Following the capital increase and the new mid-term outlook presented at its CMD, OHB is in our view...
After numerous quarters with declining NII on the back of lower policy rates, a positive rate hiking...
SciBase announced this morning that it has submitted a 510(k) premarket notification to the FDA seek...
Sivers has raised SEK700m at SEK57 per share, with a mere 3.
* Q2e: some GLP-1 ramp-up, more to come in H2e * Estimates up on FX and higher growth in Engineered ...
Redeye shares its preview of Physitrack’s Q2 2026 results, ahead of the official report on 21 July.
CHOSA Oncology’s CCO and board member Claus Frisenberg Pedersen visits Västra Hamnen and discusses t...
Redeye comments on AlzeCure Pharma’s signing of a landmark global out-licensing and collaboration ag...
Redeye comments on the outcome in IRLAB's rights issue, which was oversubscribed.
Vuxen Group redovisade en nettoomsättning om 55,8 MSEK (45,3) i Q4’25/26, motsvarande en tillväxt om...
Redeye anticipates a positive undertone in Truecaller's upcoming Q2 report (due 17 July).
AVTECH today announced a two-year extension with SouthWest worth SEK26m-36m depending on the USD/SEK...